Ablation plus immunotherapy and chemotherapy for resectable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining a tumor-destroying procedure (ablation) with immunotherapy (tislelizumab) and chemotherapy before surgery can improve outcomes for people with stage II-IIIB non-small cell lung cancer. The goal is to shrink the tumor and boost the immune system to fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stage II-IIIB non-small cell lung cancer (NSCLC) that can be surgically removed.
- You must have tumors that can be treated with ablation (a procedure that destroys cancer cells using heat or cold).
- You must be able to undergo surgery to remove the cancer completely.
- You must be in good overall health (ECOG score 0-1) and have adequate heart, lung, and organ function.
- You must not have certain genetic mutations (EGFR or ALK) or have had prior chemotherapy, radiation, or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding adebrelimab (an immunotherapy drug) to standard chemotherapy before surgery can shrink non-small cell lung cancer that can be removed. The goal is to improve the chance of successful surgery and reduce the risk of the cancer coming back.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and chemotherapy) given before and after surgery to treat stage II-IIIB non-small cell lung cancer. The goal is to see if this approach can improve outcomes for patients whose cancer can be removed surgically.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This study tests a new approach for people with early-stage lung cancer that can be removed with surgery. Before surgery, patients receive a treatment called cryo-thermal ablation to freeze and heat the tumor, along with an immunotherapy drug (toripalimab) and chemotherapy. The goal is to see if this combination shrinks tumors and improves outcomes after surgery.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.